This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Cardiovascular System  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Lessons From the CAPRIE and CURE Studies

Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD, FACC, FSCAI, FESC

Arch Intern Med. 2004;164:2106-2110.

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients with different risk levels for a cardiovascular event. We reviewed the results of the Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE) and Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trials, with special emphasis on comparing the outcomes in high-risk patients with those of the total populations in the trials. The results in the high-risk subgroups and total populations were compared by recording total event rates, absolute risk reduction, relative risk reduction, and number needed to treat. In the CAPRIE trial, the efficacy of clopidogrel was compared with acetylsalicylic acid (ASA) in the following subgroups: total population, previous coronary bypass surgery, history of more than1 ischemic event, multiple vascular beds involvement, diabetes, and hypercholesterolemia. In the CURE trial, the combination of clopidogrel and ASA was compared with ASA alone. The results in the CURE study were compared in patients who did and did not have a coronary intervention procedure, in patients with different levels of risk based on the Thrombolysis in Myocardial Infarction score and in patients with and without a history of a revascularization procedure. High-risk subgroups of patients participating in the CAPRIE and CURE studies were more responsive to the beneficial effects of clopidogrel compared with the study population as a whole. High-risk groups in the CAPRIE and CURE studies would be expected to derive enhanced benefit from treatment with clopidogrel over that achieved by ASA.

Author Affiliations: The Henderson Research Centre, Hamilton, Ontario (Dr Hirsh); and the Cleveland Clinic Foundation, Cleveland, Ohio (Dr Bhatt).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin
Donald B. Hansen
Arch Intern Med. 2005;165(11):1310.
EXTRACT | FULL TEXT  

The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin—Reply
Deepak L. Bhatt and Jack Hirsh
Arch Intern Med. 2005;165(11):1310-1311.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Patients with peripheral arterial disease in the CHARISMA trial
Cacoub et al.
Eur Heart J 2009;0:ehn534v1-10.
ABSTRACT | FULL TEXT  

The diabetic foot
Khanolkar et al.
QJM 2008;101:685-695.
ABSTRACT | FULL TEXT  

Review: Aspirin and Diabetes Mellitus: revisiting an old player
Manrique et al.
Ther Adv Cardiovasc Dis 2008;2:37-42.
ABSTRACT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Bleeding and management of bleeding
Eikelboom and Hirsh
Eur Heart J Suppl 2006;8:G38-G45.
ABSTRACT | FULL TEXT  

The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention
Chaturvedi and Yadav
Stroke 2006;37:1572-1577.
ABSTRACT | FULL TEXT  

Aspirin and clopidogrel resistance: an emerging clinical entity
Wang et al.
Eur Heart J 2006;27:647-654.
ABSTRACT | FULL TEXT  

What is the future of diabetic wound care?
Sweitzer et al.
The Diabetes Educator 2006;32:197-210.
ABSTRACT | FULL TEXT  

The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin
Hansen
Arch Intern Med 2005;165:1310-1310.
FULL TEXT  

The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin--Reply
Bhatt and Hirsh
Arch Intern Med 2005;165:1310-1311.
FULL TEXT